IPS 细胞衍生类器官市场

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, stem cell research publications, and authoritative biomedical research organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), International Society for Stem Cell Research (ISSCR), Human Organoid Innovation Hub (HOIH), California Institute for Regenerative Medicine (CIRM), UK Medicines and Healthcare products Regulatory Agency (MHRA), Japan Pharmaceuticals and Medical Devices Agency (PMDA), International Conference on Harmonisation (ICH), World Health Organization (WHO) Global Health Observatory, EU Eurostat Health Database, Organization for Economic Co-operation and Development (OECD) Health Statistics, National Science Foundation (NSF) Science and Engineering Indicators, and national biotechnology ministry reports from key markets including China National Health Commission, Japan Agency for Medical Research and Development (AMED), and UK Research and Innovation (UKRI). These sources were used to collect organoid research funding statistics, regulatory approval data for iPSC-based therapies, clinical safety studies, patent landscape analysis, and market landscape analysis for brain organoids, heart organoids, lung organoids, liver organoids, kidney organoids, and other emerging organoid technologies.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, Chief Scientific Officers (CSOs), VPs of Research & Development, regulatory affairs chiefs, and commercial directors from iPSC-derived organoid manufacturers, cell culture media providers, and biotechnology OEMs. Demand-side sources included procurement leads from contract research organizations (CROs), academic medical centers, and biopharmaceutical companies, as well as principal investigators at academic stem cell research centers, directors of pharmaceutical drug discovery programs, and chief medical officers at regenerative medicine clinics. The primary research validated market segmentation across organoid types, confirmed product pipeline timelines for organoid-based drug screening platforms, and gathered insights on clinical adoption patterns in personalized medicine, pricing strategies for organoid culture systems, and funding dynamics for stem cell research initiatives.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)

Global market valuation was derived through revenue mapping and research funding volume analysis. The methodology included:

Identification of 50+ key manufacturers and technology providers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across brain organoids, heart organoids, lung organoids, liver organoids, kidney organoids, and other emerging organoid categories

Analysis of reported and modeled annual revenues specific to iPSC-derived organoid portfolios, including culture media, matrices, and instrumentation

Coverage of manufacturers and research institutions representing 75-80% of global market share in 2024

Extrapolation using bottom-up (research funding volume × technology adoption rate by country/institution) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for drug discovery and development, disease modelling, and regenerative medicine applications